APTIOM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aptiom, and when can generic versions of Aptiom launch?
Aptiom is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred patent family members in twenty-six countries.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aptiom
A generic version of APTIOM was approved as eslicarbazepine acetate by DR REDDYS on June 29th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for APTIOM?
- What are the global sales for APTIOM?
- What is Average Wholesale Price for APTIOM?
Summary for APTIOM
| International Patents: | 100 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 3 |
| Patent Applications: | 226 |
| Drug Prices: | Drug price information for APTIOM |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for APTIOM |
| What excipients (inactive ingredients) are in APTIOM? | APTIOM excipients list |
| DailyMed Link: | APTIOM at DailyMed |
Recent Clinical Trials for APTIOM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sunovion | Phase 3 |
| Sunovion | Phase 4 |
| Stanford University | Phase 4 |
Pharmacology for APTIOM
| Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Paragraph IV (Patent) Challenges for APTIOM
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| APTIOM | Tablets | eslicarbazepine acetate | 200 mg, 400 mg, 600 mg and 800 mg | 022416 | 7 | 2017-11-08 |
US Patents and Regulatory Information for APTIOM
APTIOM is protected by fifteen US patents.
Patents protecting APTIOM
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Pharmaceutical composition comprising licarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Methods of treatment of partial onset seizures using eslicarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
Pharmaceutical composition comprising licarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Asymmetric catalytic reduction of oxcarbazepine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition comprising licarbazepine acetate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Asymmetric catalytic reduction of oxcarbazepine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Treatments involving eslicarbazepine acetate or eslicarbazepine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Treatments involving eslicarbazepine acetate or eslicarbazepine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
Therapeutical uses of eslicarbazepine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-004 | Nov 8, 2013 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for APTIOM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-002 | Nov 8, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-001 | Nov 8, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-004 | Nov 8, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for APTIOM
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| BIAL - Portela & Ca, S.A. | Zebinix | eslicarbazepine acetate | EMEA/H/C/000988 Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. |
Authorised | no | no | no | 2009-04-21 | |
| BIAL - Portela Ca, S.A. | Exalief | eslicarbazepine acetate | EMEA/H/C/000987 Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. |
Withdrawn | no | no | no | 2009-04-21 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for APTIOM
When does loss-of-exclusivity occur for APTIOM?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 5917
Patent: PROCESO DE REDUCCION CATALITICA ASIMETRICA PARA PREPARAR LOS ISOMEROS (S)-(+) Y (R)-(-) DEL COMPUESTO (10,11-DIHIDRO-10-HIDROXI-5-H DIBENZ [B.F] AZEPIN-5-CARBOXAMIDA]
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 06273874
Patent: Asymmetric catalytic reduction of oxcarbazepine
Estimated Expiration: ⤷ Sign Up
Austria
Patent: 20665
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0615970
Patent: processo para preparar (s) (+)-10,11-dihidro-10-hidróxi-5h-dibenz/b,f/azepina-5-ca rboxamida, processo para preparar (s)-(-)-10-acetoxi-10,11-dihidro-5h-dibenz/b,f/azepina-5- carboxamida e processo para preparar (r)-(+)-10-acetoxi-10,11-dihidro-5h-dibenz/b,f/azepina-5- carboxamida
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 16984
Patent: REDUCTION CATALYTIQUE ASYMETRIQUE D'OXCARBAZEPINE (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1277937
Patent: Asymmetric catalytic reduction of oxcarbazepine
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 11988
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 15346
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 15346
Patent: REDUCTION CATALYTIQUE ASYMETRIQUE D'OXCARBAZEPINE (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)
Estimated Expiration: ⤷ Sign Up
Patent: 19836
Patent: Reduction catalytique asymetrique d'oxcarbazepine (Asymmetric catalytic reduction of oxcarbazepine)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 95765
Estimated Expiration: ⤷ Sign Up
Patent: 09502893
Estimated Expiration: ⤷ Sign Up
Patent: 13173764
Patent: ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 08001291
Patent: REDUCCION CATALITICA ASIMETRICA DE OXCARBAZEPINA. (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5462
Patent: Asymmetric catalytic reduction of oxcarbazepine
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 15346
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 3467
Patent: REDUÇÃO CATALÍTICA ASSIMÉTRICA
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 39060
Patent: АСИММЕТРИЧЕСКОЕ КАТАЛИТИЧЕСКОЕ ВОССТАНОВЛЕНИЕ ОКСКАРБАЗЕПИНА (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)
Estimated Expiration: ⤷ Sign Up
Patent: 08107718
Patent: АСИММЕТРИЧЕСКОЕ КАТАЛИТИЧЕСКОЕ ВОССТАНОВЛЕНИЕ ОКСКАРБАЗЕПИНА
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 15346
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0800986
Patent: Asymmetric catalytic reduction of oxcarbazepine
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1362281
Estimated Expiration: ⤷ Sign Up
Patent: 080036212
Patent: ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 71556
Estimated Expiration: ⤷ Sign Up
Patent: 62816
Estimated Expiration: ⤷ Sign Up
United Kingdom
Patent: 15690
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering APTIOM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006120501 | ⤷ Sign Up | |
| New Zealand | 565462 | Asymmetric catalytic reduction of oxcarbazepine | ⤷ Sign Up |
| Russian Federation | 2009131075 | ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ЭСЛИКАРБАЗЕПИНА | ⤷ Sign Up |
| Austria | E520665 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for APTIOM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0751129 | 360 | Finland | ⤷ Sign Up | |
| 2214636 | C02214636/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ESLICARBAZEPINACETAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67375 02.04.2020 |
| 0751129 | CA 2009 00023 | Denmark | ⤷ Sign Up | |
| 0751129 | C300406 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ESLICARBAZEPINE, DESGEWENST IN; REGISTRATION NO/DATE: EU/1/09/514/001-020 20090421 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
